Topiramate: Pharmacokinetics and Pharmacodynamics

ABSTRACT: Topiramate is a structurally novel anti-epileptic drug with at least 3 postulated mechanisms of action including: 1) potentiation of GABA responses, 2) impairment of AMPA/kainate glutamate receptors and 3) suppression of high frequency action potential firing. It has a favourable pharmacokinetic profile with rapid absorption, good bio-availability, linear pharmacokinetics, relatively long half-life and limited pharmacokinetic drug interactions. However, topiramate can reduce the estrogen component of oral contraceptive medications. Women may require birth control preparations containing 50 (Xg of estrogen. Topiramate clearance is reduced in severe renal failure and increased by enzyme-inducing antiepileptic drugs. The dose of topiramate may have to be reduced in renal failure or when withdrawing enzyme inducers.

[1]  W. Rosenfeld,et al.  Effect of Topiramate on the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol in Patients with Epilepsy , 1997, Epilepsia.

[2]  W. Rosenfeld,et al.  Comparison of the Steady‐State Pharmacokinetics of Topiramate and Valproate in Patients with Epilepsy During Monotherapy and Concomitant Therapy , 1997, Epilepsia.

[3]  R. Nayak,et al.  Single‐Dose Pharmacokinetics and Effect of Food on the Bioavailability of Topiramate, A Novel Antiepileptic Drug , 1996, Journal of clinical pharmacology.

[4]  H. Edmonds,et al.  Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy. , 1996, Life sciences.

[5]  R. Nayak,et al.  Steady‐State Pharmacokinetics of Topiramate and Carbamazepine in Patients with Epilepsy During Monotherapy and Concomitant Therapy , 1996, Epilepsia.

[6]  A. Wauquier,et al.  Topiramate: a potent anticonvulsant in the amygdala-kindled rat , 1996, Epilepsy Research.

[7]  R. Levy.  Explanation and prediction of drug interactions with topiramate using a CYP450 inhibition spectrum , 1995 .

[8]  S. Sombati.  Effects of topiramate on sustained repetitive firing and low Mg^ -induced seizure discharges in cultured hippocampal neurons , 1995 .

[9]  T. Serikawa,et al.  Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. , 1994, European journal of pharmacology.

[10]  C. B. Davis,et al.  Topiramate: Preclinical Evaluation of a Structurally Novel Anticonvulsant , 1994, Epilepsia.

[11]  M. F. S. Mendes,et al.  Development of an instrument to assess quality of life in children with epilepsy and learning disability , 1994 .

[12]  L. Gisclon.  The steady-state pharmacokinetics of phenytoin (Dilantin) and topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy , 1994 .

[13]  D. Coulter.  Selective effects of TPM on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons , 1993 .